Lilly Announces $3.5B Pennsylvania Plant as Part of Domestic Expansion

New facility will produce injectable drugs and devices, including weight-loss treatment retatrutide.

Jan. 30, 2026 at 2:23pm

Got story updates? Submit your updates here. ›

Drugmaker Eli Lilly and Co. announced plans to build a $3.5 billion manufacturing facility in Fogelsville, Pennsylvania, as part of a broader domestic expansion. The new plant will produce injectable drugs and devices, including the company's weight-loss drug retatrutide, which is still under development. Lilly's sales of obesity and diabetes treatments like Zepbound and Mounjaro have surged, driving the company's recent record profits.

Why it matters

Lilly's investment in domestic production capacity comes as the company experiences booming demand for its obesity and diabetes medications. The new Pennsylvania plant is part of a broader expansion that also includes new facilities in Texas, Virginia, Alabama, and Indiana, underscoring Lilly's commitment to increasing its U.S. manufacturing footprint.

The details

The new $3.5 billion facility in Fogelsville, just outside Allentown, Pennsylvania, will produce injectable drugs and devices, including Lilly's weight-loss drug retatrutide, which is still in clinical trials and not yet available for public use. Construction on the plant is expected to begin this year and be completed by 2031.

  • Lilly announced the new Pennsylvania plant on January 30, 2026.
  • Construction on the $3.5 billion facility is expected to begin this year and be completed by 2031.

The players

Eli Lilly and Co.

An Indianapolis-based pharmaceutical company that manufactures and markets drugs, including the weight-loss treatment Zepbound and the diabetes drug Mounjaro, which have seen surging sales in recent quarters.

Fogelsville, Pennsylvania

The location of Lilly's new $3.5 billion manufacturing facility, which is just outside the city of Allentown.

Got photos? Submit your photos here. ›

The takeaway

Lilly's investment in a major new manufacturing facility in Pennsylvania underscores the company's commitment to expanding its domestic production capacity to meet growing demand for its lucrative obesity and diabetes treatments. This expansion is part of a broader trend of pharmaceutical companies investing in U.S. manufacturing to reduce reliance on overseas supply chains.